文献速递白血病造血干细胞移植与细胞治疗

新诊断急性髓系白血病合并高白细胞增多症患者接受异基因造血干细胞移植的长期影响:欧洲血液与骨髓移植学会急性白血病工作组分析

Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.
PubMed 文献 · Am J Hematol · 2017-05-26

该回顾性登记研究纳入357例高白细胞增多症(WBC 50 K-100 K 159例,WBC≥100 K 198例)与918例无高白细胞增多症的移植AML患者。多因素分析显示高白细胞增多症独立关联复发率增高(HR 1.55)、无白血病生存期降低(HR 1.38)和总生存期较差(HR 1.4)。

要点

  • 高白细胞增多症移植AML患者多因素分析复发风险增高(HR 1.55,95%CI 1.14-2.12,P=.004)。
  • 高白细胞增多症移植AML患者无白血病生存期降低(HR 1.38,95%CI 1.07-1.78,P=.013)。
  • 高白细胞增多症移植AML患者总生存期较差(HR 1.4,95%CI 1.07-1.84,P=.013)。

核心结论

  • 高白细胞增多症对接受造血干细胞移植的AML患者仍保留显著的预后意义。

研究设计与样本

  • 回顾性分析,使用欧洲血液与骨髓移植学会急性白血病工作组登记库。
  • 357例高白细胞增多症患者(WBC 50 K-100 K 159例,WBC≥100 K 198例)与918例无高白细胞增多症患者进行比较。

主要发现

  • 高白细胞增多症患者更年轻,有利风险细胞遗传学比例更高,FLT3和NPM1突变可能性更大。
  • 多因素分析中,高白细胞增多症独立关联复发率增高(HR 1.55,95%CI 1.14-2.12;P=.004)。
  • 多因素分析中,高白细胞增多症独立关联无白血病生存期降低(HR 1.38,95%CI 1.07-1.78;P=.013)。
  • 多因素分析中,高白细胞增多症独立关联总生存期较差(HR 1.4,95%CI 1.07-1.84;P=.013)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Up to 20% of acute myeloid leukemia (AML) patients present initially with hyperleukocytosis, placing them at increased risk for early mortality during induction. Yet, it is unknown whether hyperleukocytosis still retains prognostic value for AML patients undergoing hematopoietic stem cell transplantation (HSCT). Furthermore, it is unknown whether hyperleukocytosis holds prognostic significance when modern molecular markers such as FLT3-ITD and NPM1 are accounted for. To determine whether hyperleukocytosis is an independent prognostic factor influencing outcome in transplanted AML patients we performed a retrospective analysis using the registry of the acute leukemia working party of the European Society of Blood and Marrow Transplantation. A cohort of 357 patients with hyperleukocytosis (159 patients with white blood count [WBC] 50 K-100 K, 198 patients with WBC ≥ 100 K) was compared to 918 patients without hyperleukocytosis. Patients with hyperleukocytosis were younger, had an increased rate of favorable risk cytogenetics, and more likely to be FLT3 and NPM1 mutated. In multivariate analysis, hyperleukocytosis was independently associated with increased relapse incidence (hazard ratio [HR] of 1.55, 95% confidence interval [CI], 1.14-2.12; P = .004), decreased leukemia-free survival (HR of 1.38, 95% CI, 1.07-1.78; P = .013), and inferior overall survival (HR of 1.4, 95% CI, 1.07-1.84; P = .013). Hyperleukocytosis retains a significant prognostic role for AML patients undergoing HSCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Canaani J, Labopin M, Socié G, et al. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. Am J Hematol. 2017. PMID: 28370339. doi:10.1002/ajh.24737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。